Since Dalziel's initial description of Crohn's disease in 1913' many microbial aetiologies such as the involvement of Yersinia enterocolitica, pseudomonas-like organisms, Escherichia coli, Streptococcus faecalis L-forms, chlamydia, and mycoplasma2l' have been postulated for the disease. Currently there is a renewed interest for a putative role of mycobacteria in Crohn's disease.5 '°I n 1972, Patterson and Allen put emphasis on the similarities between Crohn's disease and Johne's disease of cattle." Johne's disease is known to be caused by Mycobacterium paratuberculosis."12 This wasting disease is characterised, as Crohn's disease, by a transmural chronic granulomatous inflammatory reaction, principally of the terminal ileum but also of the caecum, colon, and occasionally of other organs and regions of the gut. 3 Evidence of a possible aetiological link between these diseases came only recently, when Chiodini et al"6'4'5 isolated a mycobacterium species from surgical gut specimens of four patients with Crohn's disease. The mycobacterium isolated from patients with Crohn's disease was biochemically, and genetically similar to M paratuberculosis of Johne's disease. 16 The investigators hypothesised that the slow growing mycobacterium played an aetiological role in at least some cases of Crohn's disease.
Since this initial report, isolation studies of mycobacteria have given controversial data. Graham and collaborators isolated several mycobacterial species from colon tissues of Crohn's disease patients, but similar organisms could regularly be isolated from ulcerative colitis patients, patients with colon diseases other than chronic inflammatory bowel disease (nonchronic inflammatory bowel disease control group), and even healthy individuals.'7 These authors concluded that a direct association between the presence of mycobacteria in the gut and Crohn's disease or ulcerative colitis could not be established. They suggested that the isolation of mycobacteria from Crohn's disease, ulcerative colitis, non-chronic inflammatory bowel disease, and healthy gut tissues earlier favoured the hypothesis that chronic inflammatory bowel disease might be the result of an abnormal immune response to these commensally occurring mycobacteria.
If M paratuberculosis does play a role in the pathogenesis ofCrohn's disease, it is conceivable that Crohn's disease patients will either have a defective response to this mycobacterium (if the mycobacterium is commensal) or they will show an enhanced immune response to the bacterium while healthy controls will not (if the mycobacterium is a direct pathogen, or if the host is hypersensitive to the mycobacterium). Mycobacteria in general is known to give rise to T-cell mediated immune reactions. The presence of granulomas in gut specimens of patients with Crohn's disease also indicate that T cells might be involved in its pathogenesis.
There are a few well accepted parameters to assess T-cell mediated immunity to mycobacterial antigens, such Mononuclear cells (2 5 x 106) were cultured in the wells of round bottom microtitreplates. Antigens were added to obtain a final concentration of 0 5, 2 5, 10, and 44 ,ug/ml for mycobacterial antigens. Supernatants were also prepared using con A in a final concentration of 5 ,ug/ml. Supernatants were collected (10 min, x2000 g) after three days of culture (37°C, 5% CO2 in air) and stored at -20°C until testing for macrophage inhibition factor activity.
The agarose microdroplet assay was performed in principle according to Thurman et al26 using the monocytoid U937 cell-line as indicator cells. 27 The cell line was maintained and propagated in the above culture fluid at 37°C in 5% CO2 in air. Cells were harvested in the logarithmic growth phase, counted, washed (10 min, x 200 g), resuspended in a small volume of medium and transferred to a 1-5 ml conical tube, and reconcentrated by centrifugation (10 min, x200 g). The pellet was resuspended at room temperature (2 x 10' cells/ml) in a 0 2% agarose solution. This solution was prepared by dissolving 20 mg sea plaque agarose of low gelling temperature (Marine Colloids, Rockland, USA) in 1 ml phosphate buffered saline (pH 7-4) at 120°C and diluting it ten times with medium, before adding the cells.
From this cell suspension, 1 t1l droplets were centrally placed in wells of flat bottom microtitreplates (Nunc, Denmark) using a Hamilton Repeating Dispenser with a 0 05 ml gas-tight syringe (Hamilton, Reno, USA). The droplets were left to solidify at 4°C for 10-20 minutes and carefully overlaid with 0O1 ml of thawed supernatants diluted 1:1 with fresh medium. All tests were carried out in three-fold. After incubation of the covered plates for 21 h at 37°C, and 5% CO2 in air, migration areas (cell migration area minus area of the agarose droplet) were computed using a projection microscope and a graphic tablet connected with a Mop Videoplan.
Macrophage inhibition factor production was expressed as % of migration inhibition: macrophage inhibition= 100-lOOx mean migration area in antigen-stimulated cultures mean migration area in medium
Results
The U937 indicator cell system provided reproducible results; the intra-experimental variation in the migration of the indicator cells in the agarose droplets in the absence of any macrophage inhibition factor or other stimulus was less than 10%.
Ovalbumin was used as antigen to test the migration of the U937 indicator system in the presence ofa negative lymphocyte culture supernatant. In addition 10 patients with Crohn's disease, 10 patients with ulcerative colitis, and nine non-chronic inflammatory bowel disease controls were tested at four concentrations of the antigen -that is, 0 5, 2 5, 10, 44 [tg/ml, in the macrophage inhibition factor assay.
Results are shown in Figure 1 . Dose response curves were not recorded in any of the groups tested, and inhibition (or stimulation) values never exceeded a 20% limit of migration found with culture fluid alone. There was no difference in the macrophage inhibition factor assay outcomes between healthy controls, non-chronic inflammatory bowel disease patients and patients with Crohn's disease or ulcerative colitis. The data can be taken to indicate that none of the patients or healthy individuals had T-cell reactivity towards ovalbumin. On the bases of these data we considered an inhibition of migration of >20% as to represent the presence of macrophage inhibition factor in the indicator system.
Using this criterium 74% of the patients with Crohn's disease and 79% of the patients with ulcerative colitis showed a positive lymphokine (14)) (Table) . Sixty four per cent of the healthy and controls also had a positive macrophage inhibition factor assay upon con A stimulation (mean SE 52 (13) ). According to the Fisher-exact test the differences between the outcomes of the con A macrophage inhibition factor assay in Crohn's disease patients, ulcerative colitis patients and controls (p-values Crohn's disease-ulcerative colitis: 0-14; Crohn's disease-controls: 0-21; ulcerative colitis-controls: 0-92) were not statistically significant. This indicates that in general macrophage inhibition factor production of chronic inflammatory bowel disease patients towards a non-specific positive stimulus is intact and similar to that of healthy individuals.
We were able to identify two patterns of responsiveness in patients and healthy controls with regard to the macrophage inhibition factor production towards mycobacterial sonicates: (a) negative responses -that is, dose response curves similar to ovalbumin; (b) positive responses -that is, inhibitions exceeding the 20% limit in at least two or more concentrations of the sonicates tested and showing a dose response curve.
As an example of the two patterns of responsiveness the individual curves in the control, Crohn's disease, and ulcerative colitis group are shown for the sonicate ofM tuberculosis (Fig 2) . The other organisms gave similar results.
Patients with such a positive macrophage inhibition factor response to a mycobacterial sonicate are further referred to as 'responders'. The prevalence of 'responders' and 'nonresponders' to the four mycobacterial sonicates is shown in the Table. Significant differences in the prevalences between the Crohn's disease patients, ulcerative colitis patients, and controls, were not found irrespective of the mycobacterial sonicate used. The high prevalence of responders in all groups indicates that at least some ofthe sonicated mycobacteria are either commensal or must contain epitopes that occur frequently in our environment. The actual migration inhibition values of the responders in the Crohn's disease, ulcerative colitis, and control group for each of the dosages of the mycobacterial sonicates used are shown in Figure 3 . Clear dose response curves are seen, but statistically significant differences in dose response between Crohn's disease patients, ulcerative colitis patients, or non-chronic inflammatory bowel disease controls are not present.
Discussion
In this paper T-cell mediated immune responsiveness (as measured in macrophage inhibition factor assay) towards four mycobacterial species -that is, a M paratuberculosis strain isolated from Johne's disease, M kansasii strain, a M avium strain, and a M tuberculosis strain was investigated in 35 Another limitation of our study is the fact that .. macrophage inhibition factor production from peripheral blood lymphocytes may not reflect the macrophage inhibition factor production of lymphocytes in the diseased organ. As shown in a study by Holoshitz and colleagues32 on T-cell mediated immune responsiveness against mycobacteria in patients with rheumatoid arthritis a difference between the reactivity of blood T-lymphocytes and those present in the synovial tissues was found. Therefore mycobacterial specific macrophage inhibition factor production from T-lymphocytes isolated from gut specimens affected by Crohn's disease should also be investigated before making a definite conclusion.
Our findings that mycobacterial specific macrophage inhibition factor production reactivity in chronic inflammatory bowel It can also be concluded from our study that a large proportion of the healthy population showed a T-cell response towards the mycobacteria used and the responders rates varied from 59 up to 80%. The reasons for these findings may be the commensal character of some of the mycobacteria (M avium) and the cross reactivity of various mycobacterial epitopes with other environmental or microbial epitopes. This line of reasoning is in accordance with findings from earlier studies in which certain mycobacteriathat is, M kansasii, M avium-intracellulare, M scorfulaceum, M phlei) were easily recovered from food, water, and from sputum, mouth, hands, and intestines of healthy people.'7 Graham et al'7 isolated several mycobacterial species not only from the gut of patients with Crohn's disease but also from the gut of noninflammatory bowel disease patients as well as from healthy subjects. Moreover, in a recent report38 on DNA-DNA hybridisation, sequences related to mycobacterial DNA (M paratuberculosis and M avium) were detected in practically all gut specimens. This is supported by the fact that certain mycobacteria -that is, M avium, may be commensals of the gut flora. 39 Horsburgh and collaborators suggested that this explains why in patients affected by AIDS, disseminated M avium infections are often seen.4" It has recently been shown, however, that M avium super infections in AIDS patients are not just the result of invasion by ambient gut or environmental strains, but are highly strain specific. 4' In conclusion, we were unable to detect an abnormal mycobacterial specific T-cell mediated immune responsiveness in Crohn's disease or ulcerative colitis patients. These 
